About Genelex
Genelex is a company based in Seattle (United States) founded in 1987 was acquired by Invitae in March 2020. The company has 9 employees. Genelex operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter Seattle, United States
- Employees 9
- SectorsHealthcare
- Website genelex.com
- Social LinkedIn X Facebook
- Acquired by Invitae (Mar 2020)
Investors in Genelex
Genelex has secured backing from 1 investor. Prominent investors backing the company include Invitae.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Home-based genetic tests for detecting diseases are provided to individuals. | 2010 | invitae.com | San Francisco, United States |
Investor details for Genelex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Genelex
2 dated milestones of Genelex across 33 years, from founding to its latest funding, stage changes and deals.
- Founded Genelex is founded.
- Exit Acquired by Invitae.
Competitors of Genelex
Genelex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.67M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | |
| unitybiotechnology.com | 2016 | San Francisco, United States | $206M | – | Therapeutics for aging diseases are developed by targeting senescent cells. | |
| unilabs.com | 2000 | Geneva, Switzerland | – | – | Diagnostic services are provided through laboratories and radiology units. | |
| celsiustx.com | 2018 | Cambridge, United States | $148M | 50 | Single-cell RNA and genomic analysis for precision therapeutics are provided. | |
| intelliatx.com | 2014 | Cambridge, United States | $85.02M | 526 | Therapeutics using CRISPR/Cas9 are developed for various diseases. | |
| voyagertherapeutics.com | 2014 | Cambridge, United States | $105M | 183 | Gene Therapy to treat CNS diseases such as Parkinson’s disease, ALS. |
Detailed competitors of Genelex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Genelex
The website of Genelex (genelex.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▼ 12.8% vs previous month
Websites whose visitors overlap most with Genelex. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
geneticprofiles.com | geneticprofiles.com | 100% | – | – | – |
| youscript.com | 93% | 3.3K | #4,703,566 | View details | |
| labcorp.com | 91% | 14.1M | #3,241 | View details | |
| genetica.com | 86% | – | – | View details | |
| dnacenter.com | 85% | 119.4K | #350,304 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Genelex
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Genelex
Complete news archive for Genelex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Genelex
10 companies that operate in the same segment as Genelex (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Genelex
Genelex was founded in 1987.
Genelex is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Genelex has 9 employees.
Genelex was founded in 1987 and is based in Seattle, United States. Operations are focused on the pharmacogenetics sector, where DNA drug sensitivity tests and YouScript software are supplied to physicians. Adverse drug events and treatment failures are addressed through these tools. Pharmacogenetic testing is combined with medication management analytics in the YouScript Precision Prescribing System. Integration with handheld devices and electronic medical records is planned for future scaling.
Genelex's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Genelex has 1 investor. Key investors include Invitae.
Yes. Genelex was acquired by Invitae in March 2020.